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Abstract 
Ape1 is a molecule with dual functions in DNA repair and redox regulation of 
transcription factors. In Ape1 deficient mice, embryos do not survive beyond 
embryonic day 9, indicating that this molecule is required for normal embryo 
development. Currently, direct evidence of the role of Ape1 in regulating hematopoiesis 
is lacking.  We used the ES cell differentiation system and a siRNA approach to knock 
down Ape1 gene expression to test the role of Ape1 in hematopoiesis. Hemangioblast 
development from ES cells was reduced 2 to 3 fold when Ape1 gene expression was 
knocked down by Ape1 specific siRNA, as was primitive and definitive hematopoiesis. 
Impaired hematopoiesis was not associated with increased apoptosis in siRNA treated 
cells.  To begin to explore the mechanism whereby Ape1 regulates hematopoiesis, we 
found that inhibition of the redox activity of Ape1 with E3330, a specific Ape1 redox 
inhibitor, but not Ape1 DNA repair activity which was blocked using the small 
molecule, methoxyamine, affected cytokine-mediated hemangioblast development in 
vitro.  In summary, these data indicate Ape1 is required in normal embryonic 
hematopoiesis and that the redox, but not the repair endonuclease function of Ape1 is 
critical in normal embryonic hematopoietic development. 
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Introduction 
Ape1/Ref-1 is a multifunctional protein involved in apurinic/apyrimidinic 
endonuclease DNA base excision repair activity, in proofreading exonuclease activity, 
and in modulating DNA binding activity of several transcription factors including NF-
kB, Egr-1, p53, AP-1, CREB, HIF-α and members of the Pax family1. Ape1 acts on 
apurinic/apyrimidinic (AP) sites in DNA as a major member of the base excision repair 
(BER) pathway and is involved in oxidative DNA damage repair2.  Ape1 is 
ubiquitously expressed at high basal levels and in previous studies to determine the 
function of Ape1 in vivo, Ape1 was disrupted using a gene targeting strategy3. Embryos 
lacking expression of Ape1 die in utero between implantation and day 6.5, indicating 
that Ape1 is required for normal embryonic development. However, this approach does 
not allow for the determination of whether it is the redox or repair function of Ape1 that 
is crucial for embryonic development.  Furthermore, this early lethality precludes 
analysis of the role of Ape1 in hematopoiesis.  
 
Mouse embryonic stem (ES) cells are derived from the inner cell mass of the 3.5-day-
old blastocyst4,5.  ES cells retain the differentiation ability of the inner cell mass after 
many passages in the presence of leukemia inhibitory factor (LIF)6.  Removal of LIF 
results in ES cell differentiation into embryoid bodies (EB)7.  Using the ES/EB system, 
a precursor that responds to vascular endothelial growth factor (VEGF) and generates 
colonies consisting of undifferentiated blast cells was identified8.  These VEGF-
responsive blast cell colonies were shown to contain endothelial, primitive erythroid, 
and various definitive hematopoietic precursors. These cells are referred to as blast 
colony-forming cells (BL-CFC) and are thought to be cells that represent the 
hemangioblast precursor of blood and endothelial lineages.  
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Ape1 siRNA has previously been used to knock down target gene expression in several 
cell types 9-11.  In this study, we used siRNA to knock down Ape1 gene expression in 
EB cells and discovered that reduction of Ape1 by siRNA results in a significant 
decrease in the frequency of hemangioblast formation and diminished formation of 
primitive and definitive hematopoietic colonies. Additionally, using an Ape1 specific 
redox inhibitor, E3330, we demonstrate that it is the redox function of Ape1 and not the 
repair activity that is involved in hematopoietic differentiation.  These data suggest that 
Ape1 may play a critical role in embryonic hematopoiesis
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Materials and method 
Cells and reagents 
The mouse CCE ES cells (passage No.10) were kindly provided by Bill Carter in the 
mouse Transgene and knockout core facility in our institute. Cytokines LIF, VEGF, 
SCF, FGF and methylcellulose-based ES cell differentiation medium and collagenase 
were purchased from Stem Cell Inc. (Vancouver, BC, Canada). Ape1 antibodies were 
purchased from Novus Biological (Littleton, CO, USA). FITC labeled anti-mouse Flk-1 
mAb was purchased from BD Pharmingen Inc (San Diego, CA, USA). Oligofectamine 
2000 was purchased from Invitrogen (Carlsbad, CA, USA). All Ape1 dsRNA and 
scrambled Ape1 siRNAs were commercially obtained from Dharmacon (Lafayette, CO, 
USA).  The 21-base sequence was subjected to a BLAST-search (NCBI) database of 
EST libraries to ensure that only one gene was targeted. Sense strand of RNA 
oligonucleotides correspond to Ape1 (GTCTGGTAAGACTGGAATACC) was 
chemically synthesized using standard methods and HPLC purification (Dharmacon 
Inc. Lafayette, CO USA).  E3330, the redox specific inhibitor of Ape1 molecule, was 
provided by Dr. Rick Borch and Rod Nyland in Department of Medical Chemistry, 
Purdue University (Lafayette, IN, USA) 
 
In vitro differentiation of ES cells 
CCE ES cells were maintained on gelatinized tissue culture dishes (100 mm; Costar, 
Cambridge, MA, USA) in standard ES culture medium consisting of Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 15 % fetal calf serum (FCS; 
GIBCO, Grand Island, NY, USA), 0.1 mM L-glutamine, 150 mM monothioglycerol 
(MTG), penicillin 100 U/mL, streptomycin 100 mg/mL, and LIF 1000 U/mL. The 
culture medium was changed every day, and cells were passaged every 2 or 3 days12.  
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To initiate differentiation into embryonic bodies (EBs), dissociated ES cells were added 
to IMDM medium (Invitrogen co,), 15 % FBS (Fetal bovine serum) (HCC6900, Stem 
Cell Technologies, Vancouver, BC, Canada), 100 ng/ml stem cell factor (R&D System, 
Minneapolis, MN, USA) and 450 µM monothioglycerol (Sigma, St. Louis, MO, USA) 
at a cell concentration of 5 ~10x103 cells / ml plated in a 100 mm low adhesion dishes.  
 
Harvesting EBs  
EBs were removed from liquid medium IMDM. 3 day aged EBs were collected, washed 
twice with PBSA (PBS with 1 % albumin), and resuspended in 0.25 % (wt/vol) Trypsin 
mix in 15% FBS containing PBSA. The EBs were incubated at 37 °C for 5 minutes and 
dissociated into a single-cell suspension by passing through a 20-gauge needle. 
Remaining small aggregates were removed by filtration through a 40-µm mesh 
(Falcon).  EB cells were spun and resuspended in 0.5 % BSA (Path-O-Cyte 4; Miles, 
Kankakee, IL, USA) in PBSA at concentration of 5 x 106 cells/ml.  
 
Transfection of EB cells with oligos of dsRNA  
Transient transfection of siRNAs was carried out as we previously reported7,13.  Total 
EB cells were diluted with fresh medium without antibiotics and transferred to 12-well 
plates at 1 x 105 cells/well (500 µl per well). Transient transfection of dsRNAs was 
carried out using Oligofectamine 2000 (Life Technologies, Carlsbad, CA, USA).  Cells 
were untreated (control), or treated with scrambled Ape1 siRNA (25~50nM), or Ape1 
siRNA (25~50nM).  
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Clonogenic cell assay 
For hemangioblast assay, after siRNA transfection, day-3 EB cells were mixed with 
IMDM, 20% FCS, 10% BSA (Stem Cell Technology), 100 µg/ml bovine transferrin, 
10ng/ml bovine insulin, 0.1 mmol/L MTG, 1% methylcellulose, and distributed to 35-
mm bacterial-grade dishes at 104 cells/plate with VEGF, SCF, DT4 conditional medium 
(CM). For primitive erythroid cell (Ery-P) assay, day 6 EB cells were cultivated with 
EPO at 5 IU/ml as previously described14.  For granulocyte-macrophage (CFU-GM) 
colony assay, day 10 EB cells were cultured with granulocyte-macrophage colony-
stimulating factor (GM-CSF) at 10 ng/ml and macrophage colony-stimulating factor 
(M-CSF) at 5 ng/ml 14. 
 
RT-PCR 
Total RNA was extracted from undifferentiated ES cells and EB cell populations by 
using TRIZOL (Invitrogen. USA), Reverse transcription was performed using 
Superscript II reverse transcriptase (GIBCO BRL, Carlsbad, CA, USA), and PCR was 
performed using Pyrobest DNA polymerase. Primer sequences for Brachyury, Flk-1, 
and scl genes have been reported8. The primer sequence of β-actin gene has been 
reported15.     
 
Western blot analysis 
Whole cell extracts were prepared using nuclear protein extract buffer (Laribee and 
Klemsz, 2001) from both Ape1-siRNA or scrambled siRNA treated and untreated cells.  
The cell lysates were separated by SDS-polyacrylamide electrophoresis using a 10% 
(w/v) polyacrylamide resolving gel and transferred electrophoretically to a nitro-
cellulose membrane. The blots were blocked with 5% TBS/T buffer for 1 hr. 
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Immunobloting was performed using the Ape1 primary monoclonal antibody (Novus 
Biologicals, Littleton, CO, USA) at a 1:400 dilution at room temperature, and the 
peroxidase-conjugated secondary Abs (Amersham Pharmacia, USA) over night at 4 ºC. 
This antibody has been extensively used by us and others11,16-20 All immunoblots were 
visualized by enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech, 
USA). 
 
Inhibition of DNA repair domain of Ape1 with MX and redox domain with E3330.  
E3330 is a specific inhibitor of redox activity of Ape1 protein, while MX is a specific 
inhibitor of the DNA repair (AP endonuclease) function of Ape1 protein. MX does not 
specifically bind to Ape1, but binds to the abasic site that is recognized by Ape1 and 
prevents Ape1’s ability to cleave the AP site 21-25.  
 
E3330 has been shown to be a very specific inhibitor of Ape1 redox function. Far-
western blots, and binding assays between radiolabeled E3330 and proteins renatured 
on membrane blots, demonstrated that 14C-labeled E3330 specifically bound to both 
recombinant APE1 and purified APE1 from cell nuclear extracts26.  The binding 
constant of APE1 and E3330 was estimated by surface plasmon resonance analysis 
(SPR) resulting in a kinetic constant value of 1.6 nM which suggests a specific 
interaction between APE1 and E333026.  Therefore, E3330 is a specific inhibitor of 
APE1 redox function.  E3330 does not affect the repair function of Ape1 (Kelley and 
Luo, unpublished data).  
 
To verify the role of Ape1 in hemangioblast development via redox domain or DNA 
repair domain, various doses of E3330 (10 -100 µM) or MX (1-10mM) were added to 
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standard hemangioblast culture. Hemangioblast colonies were scored after 4 days of 
culture.  
 
Cell cycle analysis 
EB cells were treated with either scrambled siRNA or Ape1 siRNA. After 48 hours of 
culture, cells were washed with PBS, and resuspended in 400 µL of  hypotonic buffer 
(0.15% Triton-X100 and 20 µg/ml of RNase A) containing 50 µg/ml of  Propidium 
Iodide ( PI), and analyzed using FACScan (BD Bioscience, Mountain view, CA).  
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Results  
Ape1 is expressed in both undifferentiated and differentiated ES cells 
To examine whether Ape1 is expressed in ES cells and differentiated ES cells, we 
isolated total cell protein from ES cells, and day 3, 6, or 10 EB cells. Western blot 
analysis showed that Ape1 protein is detectable in both ES cells and EB cells (Fig.1A). 
Further experiments showed that Ape1 siRNA, but not scrambled control siRNA, is 
effective to knockdown Ape1 gene expression in EB cells when probed by western blot 
analysis after 48 h of siRNA transfection (Fig.1B). 
 
Normal hemangioblast development from ES cell development 
ES cells differentiate to EBs in the absence of LIF in culture. Day 3 EB cells replated 
into culture wells with VEGF and SCF results in the emergence of hemangioblast 
colonies. Some residual undifferentiated ES cells in EB were able to differentiate into a 
cell mass called secondary EBs, that are round bodies with a smooth edge and are easy 
to distinguish from hemangioblast colonies (Fig. 2A). We separately collected BL-
CFCs or 2nd EBs and RT-PCR analysis revealed that they differ in their gene expression 
pattern (Fig. 2B).  Knockdown of Ape1 gene expression results in a decrease of BL-
CFC formation and an increase in the 2nd EB numbers in the culture (Fig. 2C,D).  
 
Ape1 is essential for both primitive and definitive hematopoiesis 
To test the role of Ape1 in primitive erythroid progenitor (Ery-P) cell development, day 
6 EBs were dissociated and EB cells were replated in methylcellulose culture medium 
supplemented with plasma derived serum and with erythropoietin. Knockdown of Ape1 
expression in day 6 EB cells blunted their potential to form Ery-P (Figure 3A). To 
determine whether a reduction of Ape1 expression affected definitive hematopoiesis, 
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Ape1 siRNA was introduced into dissociated day 10 EB cells followed by progenitor 
assays.  Cells with reduced Ape1 expression generated significantly fewer definitive 
erythroid colonies (Ery-D) compared to untreated cells or cells transfected with 
scrambled siRNA (Figure 3B). Moreover, to examine myeloid differentiation, CFU-
GMs were scored by replating control or Ape1 siRNA-treated day 10 EB cells in the 
presence of Epo, SCF, GM-CSF and IL-3. Our results indicated that the frequencies of 
CFU-GM colony were decreased in Ape1 siRNA-transfected group compared with the 
control scrambled siRNA-transfected group (Fig.3C) (P < 0.05). Consistent with the 
levels of Ape1 expression detected by Western blot analysis in cells transfected with 25 
nM and 50 nM Ape1 siRNA (Figure 1B), no significant difference in hematopoietic 
colony frequency between cells treated with 25 nM or 50 nM of Ape1 siRNA was 
observed (Figure 3A, 3B, and 3C). As CD34+ day 10 EB cells contain hematopoietic 
progenitor cells7,13, we then sorted CD34+ EB cells from day 10 EBs and treated cells 
with scrambled or Ape1 siRNA. Our data revealed that knockdown of Ape1 gene 
expression in these cells reduced their ability to form colonies of Ery-D, CFU-GM and 
CFU-Mix (Fig. 4A, B, C).  
 
Knockdown of Ape1 gene expression in EB cells did not induce apoptosis in these cells 
To determine whether or not knockdown of Ape1 gene expression in EB cells induced 
apoptosis, siRNA transfected cells were harvested after 48 hours of transfection and 
stained with Annexin V and PI. The cells were then analyzed by FACS. As shown in 
Figure 5, knockdown of Ape1 gene expression with siRNA did not trigger apoptosis in 
EB cells. In contrast, cells treated with IFN-γ displayed robust apoptosis (Fig. 5).  
 
Inhibition of Ape1 redox activity by E3330 but not DNA repair activity by 
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methoxyamine affects hemangioblast development in vitro 
To address which functional domain in the Ape1 molecule may play the major role in 
regulation of hematopoiesis, we added the Ape1 redox inhibitor E3330 (0 - 100 µM) or 
the Ape1 abasic site excision inhibitor, MX (0 ~ 10mM) to add to the cultured EB 
cells. Inhibition of Ape1 redox activity by E3330, but not Ape1 DNA repair activity by 
MX affected cytokine-mediated hemangioblast development in vitro (Fig.6).  
Furthermore, the inhibition of BL-CFC and Ery-P colony formation via E3330 was 
dose dependent.  
 
Knock down of Ape1 in EB cells induces G1 arrest in EB cells 
To examine whether or not the decrease in frequency of hematopoietic colonies was 
caused by low cell proliferation, we performed cell cycle analysis of the cells treated 
with Ape1 siRNA. As shown in Figure 7, reduction of Ape1 gene expression with Ape1 
siRNA, but not scrambled siRNA, significantly increased day 3 EB cells or Flk-1+ EB 
cells in the G1 phase and decreased the percent of cells in S phase. This indicates that 
knockdown of Ape1 gene expression in EB cells resulted in a decrease in the G1/S 
transition of the cell cycle in EB cells.   
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Discussion 
We have demonstrated that the knockdown of Ape1 gene expression in mouse ES cells 
results in a decrease in the formation of hemangioblast, primitive, and definitive 
hematopoietic colony frequencies. Our study also reveals that knockdown of Ape1 gene 
expression in EB cells affected the G1/S transition of the cell cycle in these cells. 
Further studies showed that only inhibition of Ape1 redox activity, but not Ape1 DNA 
repair activity diminished hematopoiesis. 
 
ES cell differentiation is a valuable system to study molecular regulation in embryonic 
hematopoietic development. In the absence of LIF, ES cells differentiate into EBs after 
a 3 day differentiation27. Day 3 EB cells include Flk-1+ BL-CFC cells that form 
colonies in culture when VEGF is supplied8.  Flk1 and SCL are molecular determinants 
of the hemangioblast and expression of both these molecules is required for colony 
formation28. BL-CFC represent the in vitro equivalent of the hemangioblast and, as 
such, one of the earliest stages of hematopoietic development described to date. 
Functional studies have demonstrated that some of these blast colonies contain 
primitive and definitive hematopoietic precursors as well as precursors that give rise to 
adherent endothelial-like cells.  Hemangioblast development can be regulated by a 
number of factors. TPO alone supported BL-CFC formation and nearly doubled the 
number of BL-CFC when added together with VEGF and SCF29.  The homeoprotein 
Hex is essential for hemangioblast differentiation into definitive embryonic 
hematopoietic progenitors30. We recently described the positive regulatory role of the 
protein tyrosine phosphatase Shp-2 in hemangioblast development and implicated Shp-
2 as an important mediator of FGF augmentation of BL-CFC activity in vitro14.  In the 
present study, we identified a novel role of Ape1 as a regulatory molecule in 
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hemangioblast development.  The reduction in BL-CFC resulting from decreased Ape1 
expression in the EB, may result in diminished production of both primitive and 
definitive hematopoietic progenitors.  It is interesting to contemplate that knockdown of 
Ape1 expression with siRNA may have affected emergence of the BL-CFC from 
mesoderm whereas, use of the Ape1 redox inhibitor molecule E3330 may have had a 
more direct effect on differentiation of the BL-CFC toward hematopoietic progenitors. 
To address whether a reduction in Ape1 expression directly influences progenitor 
differentiation we isolated and knocked down Ape1 expression in this cell population 
that contains primary hematopoietic progenitor cells. 
 
Changes in expression of Ape1 have been correlated with myeloid differentiation in 
HL60 leukemic cells induced by RA or DMSO31.  However, the regulatory role of Ape1 
in myeloid differentiation of primary hematopoietic stem/progenitor cells has not 
examined. Our study clearly demonstrated that Ape1 is essential for GM-CSF and other 
cytokines to stimulate myeloid hematopoiesis, as knockdown of Ape1 expression in 
CD34+ cells resulted in significant reduction of erythroid and myeloid progenitors in 
vitro. Therefore, we propose that Ape1 regulates normal erythromyelopoiesis.   
 
In previous studies, PDGF-BB stimulated cell cycle progression from G0/G1 to S in 
smooth muscle cells, with one of the postulated steps being redox-regulation of AP-1 by 
Ape1 protein32.  Therefore, we wanted to see if Ape1 may play a role in growth factor 
stimulated cell cycle regulation.  We report here that Ape1 regulates cell cycle status in 
hematopoietic progenitors and that Ape1 also positively regulate G1/S transition in EB 
cells.  The cell cycle arrest of Ape1 siRNA treated EB cells may be one mechanism to 
explain diminished hematopoietic CFC activity reported here.  Future studies will need 
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to prove how Ape1 may regulate cyclin dependent kinases and cyclins that are critical 
for G/S transition.   
 
In conclusion, this study presents direct evidence that Ape1 positively regulates 
embryonic hematopoiesis through its redox function.  However, the target of Ape1’s 
redox signaling has not been identified by this type of analysis and additional studies 
will need to address which downstream target or targets are involved in this pathway. 
As this study was limited to investigation of the regulatory role of Ape1 in embryonic 
hematopoiesis using the ES cell system, further studies to identify a possible role for 
Ape1 in adult myelolymphoid development may prove insightful.   
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Figure Legends 
Fig.1. Ape1 siRNA is efficient to knockdown target gene expression in EB cells. A). 
Western blot analysis of Ape1 protein is expression both in ES and EB cells at different 
ages; days 3, 6 and 10. B). Silencing of endogenous Ape1 gene by Ape1 siRNA. 
Western blot analysis demonstrates that Ape1 siRNA efficiently knocks down Ape1 
gene expression: lane 1: untreated cells; lane 2: cells treated with 25 nM scrambled 
siRNA; lane 3: cells treated with Ape1 siRNA at 5 nM; lane 4: cells treated with Ape1 
siRNA at 25 nM; lane 5. The cells were treated with Ape1 siRNA at 50 nM. 
 
Fig.2. Knockdown of Ape1 expression results in a decreased frequency of BL-CFC 
formation.  A) The distinct morphology between BL-CFC and 2nd EB are depicted. 
(x20).  B) The individual BL-CFC or 2nd EB colonies were collected separately. mRNA 
was extracted and RT-PCR assay revealed the distinct phenotype between these two 
cell types; BL-CFC express Flk-1 and scl genes, but not the brachyury gene. In contrast, 
2nd EB cells express the brachyury gene, but not Flk-1 and scl genes.  C) 
Hemangioblast progenitor assay indicated that knockdown of Ape1 gene expression 
with Ape1 siRNA, but not scrambled siRNA day 3 EB cells resulted in a decrease in 
BL-CFC formation. *P<0.05 comparing Ape1 siRNA to scrambled siRNA, treatment 
with transfection reagent (OFA2000), or no treatment. Data represent the mean ± SD 
for 3 experiments. D). Knockdown of Ape1 gene expression day 3 EB cells resulted in 
an increase in secondary EB formation in the culture. *P<0.05 comparing Ape1 siRNA 
to scrambled siRNA, treatment with transfection reagent (OFA2000), or no treatment. 
Data represent the mean ± SD for 3 experiments. 
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Fig. 3.  Reduction of Ape1 expression by siRNA abrogates primitive and definitive 
hematopoiesis. A) Cells derived from day 6 CCE EBs were transfected with either 
Ape1 siRNA, or scrambled siRNA and plated for primitive progenitor assays (Ery-D). 
B) Cells derived from day 10 EBs were transfected with 25 nM or 50 nM of Ape1 
siRNA1, or scrambled siRNA and plated for either definitive erythroid progenitor 
assays (Ery-D) or C) granulocyte-macrophage colony assays (CFU-GM).  At both 25 
nM and 50 nM of Ape1 siRNA in all assays conducted, significantly fewer progenitors 
developed. *P<0.05 comparing cells transfected with Ape1 siRNA to that of scrambled 
siRNA for all progenitor assays conducted. Data represents the mean + SD for 3 
experiments.  
 
Fig. 4. Reduction of Ape1 expression by siRNA in CD34+ EB10 cells abrogates 
definitive hematopoiesis. A) CD34+ cells derived from day 10 CCE EBs were 
transfected with either Ape1 siRNA, or scrambled siRNA and plated for definitive 
erythroid progenitor ( Ery-D) assays. B) CD34+ EB cells derived from day 10 EBs were 
transfected with 25 nM or 50 nM of Ape1 siRNA, or scrambled siRNA and plated into 
granulocyte-macrophage colony (CFU-GM) assays, or
 C) mixed lineage colony assays 
(CFU-Mix). At both 25 nM and 50 nM of Ape1 siRNA in all CD34+ EB cells derived 
from day10 EBs were transfected with 25 nM or 50 nM of Ape1 siRNA, or scrambled 
siRNA and plated into mixed progenitor colony (CFU-Mix) assay. There are 
significantly fewer progenitors developed. *P<0.05 comparing cells transfected with 
Ape1 siRNA to that of scrambled siRNA for all progenitor assays conducted. Data 
represent the mean + SD for 3 experiments. 
 
Fig. 5.  Knockdown of Ape1 expression in EB3 cells or sorted CD34+ EB10 cells 
did not trigger apoptosis. EB 3 or CD34+ day 10 EB cells were transfected with 
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control siRNA or Ape1 siRNA, after 48 hours of transfection, cells were harvested and 
stained with Annexin V and PI.  Double Annexin V and PI positive cells in staining are 
scored as apoptotic cell in FACS analysis.  In a separate group, cells were treated with 
IFN-γ (500 IU) as positive control in apoptosis induction. (*P<0.01) 
 
Fig. 6.  Inhibition of redox activity of Ape1 but not base excision repair (BER) 
activity of Ape1 reduce BL-CFC and Ery-P formation. A). In the BL-CFC assay, 
EB 3 cells were treated with VEGF, SCF, and various dose of E3330 (0 to 100 nM) or 
MX (0 to 10 µM) as indicated in the culture. After 4 days culture, the BL-CFC colony 
are scored and the number is shown.  Results shown are representative of three 
independent experiments, each performed in triplicate. Mean values significantly 
different from control cells (untreated or treated with DMSO) are indicated. *P<0.05; 
**P<0.01). B). In Ery-P assay, EB 6 cells were treated with Epo and various dose of 
E3330 (0 to 100 nM) or MX (0 to 10 µM).  After 7 days culture, Ery-P colony are 
scored.  Results shown are representative of three independent experiments, each 
performed in triplicate.  Mean values significantly different from control cell (untreated 
or treated with DMSO) are indicated. *P<0.05; **P<0.01). 
 
Fig. 7.  Ape1 regulates cell cycle G1-S transition in day 3 EB cells.  Day 3 EB cells 
or Flk-1+ day 3 EB cells were treated with either transfection reagent (Oligofectamine 
2000) alone, scrambled siRNA (25 nM) or Ape1 siRNA (25 nM) for 48 hours. Cells 
were collected, permeablized and stained with PI prior to flow cytometry to determine 
the percentage of cells in G1 and S phase. Open bars represent day 3 EB cells and solid 
black bars represent Flk-1+ day 3 EB cells. A). Percentage of G1 phase cells B). 
 24
Percentage of S phase cells. Bars represent means ± SD of triplicate experiments. 
*P<0.05. 
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